Catalent Expands its Advanced Aseptic, Glass-Free Injectable Platform with New Advasep Lock Delivery Technology
Catalent has announced the launch of Advasept Lock, a stopper-less, glass- and needle-free vial for the safe and efficient delivery of injectable medications. Easily opened, Advasept Lock attaches to a luer syringe, combining a safe, convenient and functional container closure with the security of an advanced aseptic filling solution.
Like the rest of Catalent’s advanced, aseptic Advasept technology family, Advaesept Lock addresses many sterile manufacturing challenges by automating the container formation and filling of the drug product into a glass-free container closure, eliminating glass particulates and delamination issues, and drastically reducing the risk of foreign particle and microbial contamination. Minimizing the risk of these types of manufacturing issues has the potential to improve the reliability of supply that targets the root cause of many generic injectable drug shortage issues.
The technology also offers safety advantages, as no needle is required for the withdrawal of the vial contents, while the design avoids the risk of sharps injuries associated with the opening of traditional ampoules. Additionally, through efficient design of the manufacturing process, Advasept Lock is a cost effective solution compared to traditional glass vials.
The Advasept Lock technology is available in 1 mL, 3 mL and 5 mL container closures but may be custom designed to meet specific brand or delivery needs.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.